First and only FDA-cleared PK dosing software now available to help healthcare professionals create personalized treatment regimens for patients 16 and older with hemophilia A1
CAMBRIDGE, MA, USA I March 5, 2018 I Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced the U.S. availability of myPKFiT for ADVATE [Antihemophilic Factor (Recombinant)], a free web-based, Rx software that is the first and only pharmacokinetic (PK) dosing software cleared by the U.S. Food and Drug Administration (FDA) for use with hemophilia A patients 16 and older weighing at least 45 kilograms and treated with ADVATE.1 The software generates a patient’s estimated individual PK profile, which aids healthcare professionals in personalizing a patient’s prophylaxis ADVATE dose and schedule.1
“A version of myPKFiT has already been widely adopted in Europe since 2014, and we’ve seen how important it has been in helping physicians develop personalized dosing regimens tailored to the specific needs of their patients,” said Andreas Busch, Global Head of Research and Development, Shire. “As part of our commitment to precision medicine, we are pleased to bring this innovative application to physicians and patients in the United States.”
The myPKFiT for ADVATE software offers an innovative approach to estimating a patient’s PK curve, a key measure for assessing drug exposure over time.1,2 With myPKFiT for ADVATE, healthcare professionals can now estimate a full PK curve with as few as two measurable blood samples, compared to the 9 to 11 recommended by the International Society on Thrombosis and Haemostasis (ISTH) guidelines.1,3
“We understand that people with hemophilia have their own treatment goals, needs and challenges that require a customized approach to care,” said Michael Tarantino, M.D., Medical Director and President, The Bleeding and Clotting Disorders Institute. “The myPKFiT software enables healthcare professionals to gain an even clearer picture of their patients’ treatment needs to develop an ADVATE prophylaxis dose and schedule that’s truly tailored to each individual patient.”
Hemophilia A, the most common type of hemophilia, is a rare bleeding disorder that causes longer-than-normal bleeding due to a lack of clotting factor VIII (FVIII) in the blood.4 The severity of hemophilia A is determined by the amount of factor in the blood, with more severity associated with lower amounts of factor.5 More than half of patients with hemophilia A have the severe form of the condition.5 Hemophilia primarily affects males, with an incidence of one in 5,000 male births in the United States. 6
myPKFiT for ADVATE software is Rx Only. For safe and proper use of the myPKFiT for ADVATE software, please refer to the complete instructions for use in the User Manual.
myPKFiT for ADVATE Indications for Use8
The myPKFiT software is intended for use by licensed healthcare professionals (HCPs) who are familiar with hemophilia care. The myPKFiT software can be used to generate ADVATE dosage amount and frequency recommendations for routine prophylaxis for an individual patient 16 years of age and older and body weight of 45 kg or greater, using that patient’s age and body weight information and local laboratory FVIII one-stage clotting activity measurements of sparse samples collected from that patient.
A minimum of two sparse sampling points are required at the recommended 3-4 hours (± 30 minutes) and at 24-32 hours (±1 hour) post-infusion.
HCPs will also be able to evaluate various prophylaxis dose regimens tailored to an individual patient’s needs and treatment plan.
The software output may be used to guide decisions on appropriate ADVATE dose and infusion intervals to maintain FVIII activity levels at or above a user specified minimum FVIII activity level between 1% to 3% above natural baseline for an individual patient in accordance with the FDA-approved dosing recommendations provided in the ADVATE Prescribing Information (PI).
myPKFiT should only be used to evaluate prophylactic dosing regimens for hemophilia A patients treated with ADVATE, as per the ADVATE Prescribing Information (PI).
myPKFiT for ADVATE is not indicated for the treatment of von Willebrand disease. myPKFiT for ADVATE should not be used for patients who have developed neutralizing antibody (inhibitor) to FVIII products.
About ADVATE
ADVATE is a full-length (derived from the complete FVIII gene) recombinant FVIII product that is processed without any blood-based additives.9
ADVATE is currently approved in 69 countries worldwide, including the United States, Canada, 28 countries in the European Union, Algeria, Argentina, Australia, Brazil, Brunei, Chile, China, Colombia, Ecuador, Hong Kong, Iceland, India, Iraq, Israel, Japan, Kuwait, Macau, Malaysia, Mexico, Morocco, New Zealand, Norway, Panama, Puerto Rico, Qatar, Russia, Saudi Arabia, Serbia, Singapore, South Korea, Suriname, Switzerland, Taiwan, Tunisia, Turkey, Ukraine, Uruguay, and Venezuela.
ADVATE [Antihemophilic Factor (Recombinant)] Important Information
Indications
ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:
· Control and prevention of bleeding episodes.
· Perioperative management.
· Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
ADVATE is not indicated for the treatment of von Willebrand disease.
About Shire
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey. www.shire.com
References:
- U.S. Food and Drug Administration, Center for Biologic Evaluation and Research Office of Tissues and Advanced Therapies. myPKFiT for ADVATE Approval Letter BK170028, December 18, 2017.
- Gustafson DL and Bradshaw-Pierce EL. Fundamental Concepts in Clinical Pharmacology. M. Hidalgo et al. (eds.), Principles of Anticancer Drug Development, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-7358-0_2. Accessible at: http://media.axon.es/pdf/83236_2.pdf
- Lee M et al. “Scientific and Standardization Committee Communication The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors.” ISTH Website. https://c.ymcdn.com/sites/www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/fviiipharmaco.pdf.
- World Federation of Hemophilia. “What is hemophilia?” World Federation of Hemophilia website. http://www.wfh.org/en/page.aspx?pid=646.
- National Hemophilia Foundation. “Hemophilia A.” National Hemophilia Foundation website. https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Hemophilia-A.
- Centers for Disease Control and Prevention. “Hemophilia Data & Statistics”. CDC website. https://www.cdc.gov/ncbddd/hemophilia/data.html.
- Securities and Exchange Commission. “General Form for Registration of Securities, Baxalta Incorporated”. 2014 Accessible at: https://www.sec.gov/Archives/edgar/data/1620546/000119312516431188/d76818ds1a.htm
- myPKFiT Device User Manual. Baxter Healthcare Corporation; 2015.
- ADVATE Prescribing Information.
SOURCE: Shire
Post Views: 34
First and only FDA-cleared PK dosing software now available to help healthcare professionals create personalized treatment regimens for patients 16 and older with hemophilia A1
CAMBRIDGE, MA, USA I March 5, 2018 I Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced the U.S. availability of myPKFiT for ADVATE [Antihemophilic Factor (Recombinant)], a free web-based, Rx software that is the first and only pharmacokinetic (PK) dosing software cleared by the U.S. Food and Drug Administration (FDA) for use with hemophilia A patients 16 and older weighing at least 45 kilograms and treated with ADVATE.1 The software generates a patient’s estimated individual PK profile, which aids healthcare professionals in personalizing a patient’s prophylaxis ADVATE dose and schedule.1
“A version of myPKFiT has already been widely adopted in Europe since 2014, and we’ve seen how important it has been in helping physicians develop personalized dosing regimens tailored to the specific needs of their patients,” said Andreas Busch, Global Head of Research and Development, Shire. “As part of our commitment to precision medicine, we are pleased to bring this innovative application to physicians and patients in the United States.”
The myPKFiT for ADVATE software offers an innovative approach to estimating a patient’s PK curve, a key measure for assessing drug exposure over time.1,2 With myPKFiT for ADVATE, healthcare professionals can now estimate a full PK curve with as few as two measurable blood samples, compared to the 9 to 11 recommended by the International Society on Thrombosis and Haemostasis (ISTH) guidelines.1,3
“We understand that people with hemophilia have their own treatment goals, needs and challenges that require a customized approach to care,” said Michael Tarantino, M.D., Medical Director and President, The Bleeding and Clotting Disorders Institute. “The myPKFiT software enables healthcare professionals to gain an even clearer picture of their patients’ treatment needs to develop an ADVATE prophylaxis dose and schedule that’s truly tailored to each individual patient.”
Hemophilia A, the most common type of hemophilia, is a rare bleeding disorder that causes longer-than-normal bleeding due to a lack of clotting factor VIII (FVIII) in the blood.4 The severity of hemophilia A is determined by the amount of factor in the blood, with more severity associated with lower amounts of factor.5 More than half of patients with hemophilia A have the severe form of the condition.5 Hemophilia primarily affects males, with an incidence of one in 5,000 male births in the United States. 6
myPKFiT for ADVATE software is Rx Only. For safe and proper use of the myPKFiT for ADVATE software, please refer to the complete instructions for use in the User Manual.
myPKFiT for ADVATE Indications for Use8
The myPKFiT software is intended for use by licensed healthcare professionals (HCPs) who are familiar with hemophilia care. The myPKFiT software can be used to generate ADVATE dosage amount and frequency recommendations for routine prophylaxis for an individual patient 16 years of age and older and body weight of 45 kg or greater, using that patient’s age and body weight information and local laboratory FVIII one-stage clotting activity measurements of sparse samples collected from that patient.
A minimum of two sparse sampling points are required at the recommended 3-4 hours (± 30 minutes) and at 24-32 hours (±1 hour) post-infusion.
HCPs will also be able to evaluate various prophylaxis dose regimens tailored to an individual patient’s needs and treatment plan.
The software output may be used to guide decisions on appropriate ADVATE dose and infusion intervals to maintain FVIII activity levels at or above a user specified minimum FVIII activity level between 1% to 3% above natural baseline for an individual patient in accordance with the FDA-approved dosing recommendations provided in the ADVATE Prescribing Information (PI).
myPKFiT should only be used to evaluate prophylactic dosing regimens for hemophilia A patients treated with ADVATE, as per the ADVATE Prescribing Information (PI).
myPKFiT for ADVATE is not indicated for the treatment of von Willebrand disease. myPKFiT for ADVATE should not be used for patients who have developed neutralizing antibody (inhibitor) to FVIII products.
About ADVATE
ADVATE is a full-length (derived from the complete FVIII gene) recombinant FVIII product that is processed without any blood-based additives.9
ADVATE is currently approved in 69 countries worldwide, including the United States, Canada, 28 countries in the European Union, Algeria, Argentina, Australia, Brazil, Brunei, Chile, China, Colombia, Ecuador, Hong Kong, Iceland, India, Iraq, Israel, Japan, Kuwait, Macau, Malaysia, Mexico, Morocco, New Zealand, Norway, Panama, Puerto Rico, Qatar, Russia, Saudi Arabia, Serbia, Singapore, South Korea, Suriname, Switzerland, Taiwan, Tunisia, Turkey, Ukraine, Uruguay, and Venezuela.
ADVATE [Antihemophilic Factor (Recombinant)] Important Information
Indications
ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:
· Control and prevention of bleeding episodes.
· Perioperative management.
· Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
ADVATE is not indicated for the treatment of von Willebrand disease.
About Shire
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey. www.shire.com
References:
- U.S. Food and Drug Administration, Center for Biologic Evaluation and Research Office of Tissues and Advanced Therapies. myPKFiT for ADVATE Approval Letter BK170028, December 18, 2017.
- Gustafson DL and Bradshaw-Pierce EL. Fundamental Concepts in Clinical Pharmacology. M. Hidalgo et al. (eds.), Principles of Anticancer Drug Development, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-7358-0_2. Accessible at: http://media.axon.es/pdf/83236_2.pdf
- Lee M et al. “Scientific and Standardization Committee Communication The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors.” ISTH Website. https://c.ymcdn.com/sites/www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/fviiipharmaco.pdf.
- World Federation of Hemophilia. “What is hemophilia?” World Federation of Hemophilia website. http://www.wfh.org/en/page.aspx?pid=646.
- National Hemophilia Foundation. “Hemophilia A.” National Hemophilia Foundation website. https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Hemophilia-A.
- Centers for Disease Control and Prevention. “Hemophilia Data & Statistics”. CDC website. https://www.cdc.gov/ncbddd/hemophilia/data.html.
- Securities and Exchange Commission. “General Form for Registration of Securities, Baxalta Incorporated”. 2014 Accessible at: https://www.sec.gov/Archives/edgar/data/1620546/000119312516431188/d76818ds1a.htm
- myPKFiT Device User Manual. Baxter Healthcare Corporation; 2015.
- ADVATE Prescribing Information.
SOURCE: Shire
Post Views: 34
